Stengone Carmine N. 4

What Happened

• Carmine N. Stengone, CEO, President and Director of Contineum Therapeutics (CTNM), exercised stock options and sold shares on Feb 11, 2026. The filing shows an exercise/acquisition of 400 shares at $1.26 per share (cost $504) and an open‑market sale of 400 shares at $16.00 per share (proceeds $6,400). The report also lists a 400‑share derivative disposition at $0.00 (see details below).

Key Details

• Transaction date: 2026-02-11; Form 4 filed: 2026-02-13 (within the usual 2-business-day filing window).
• Exercise: 400 shares acquired at $1.26 each (total $504).
• Sale: 400 shares sold in the open market at $16.00 each (total proceeds $6,400).
• Derivative entry: 400 shares disposed at $0.00 (filing shows this as a derivative conversion/disposition).
• Shares owned after transaction: Not specified in the excerpt of the filing provided.
• Notable footnotes: Transactions were executed under a 10b5‑1 trading plan adopted Sept 23, 2025 (F1). Filing notes prior ESPP purchases of 1,246 and 2,096 shares in 2024 and 2025 respectively (F2). The underlying stock options are fully vested and exercisable (F3).

Context

• This was an exercise of options followed by an immediate sale — a common, routine transaction for insiders to realize gains or cover exercise costs. The $0.00 derivative disposition typically indicates shares were surrendered/withheld as part of the exercise or settlement process (e.g., to cover taxes or option costs), as recorded in the filing. Because the trade was made under a pre‑arranged 10b5‑1 plan, it follows an automated plan rather than an ad‑hoc decision.